Vyne Therapeutics Inc.

Vyne Therapeutics Inc. company information, Employees & Contact Information

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBET™ Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with significant unmet medical needs. BETs are a family of proteins that are believed to play a causal role in the regulation of inflammatory genes that are implicated in numerous diseases. VYNE has done the first formative work in applying BET inhibition to the treatment of autoimmune disease. The company’s leadership is demonstrated in clinical development, where VYNE is building a superior body of evidence that informs the advancement of its two lead product candidates: VYN201 for the treatment of vitiligo; and VYN202, a highly potent and selective BET inhibitor that offers promise across a broad array of chronic autoimmune indications. To learn more about us and our pipeline, visit vynetherapeutics.com. Read our Social Media Guidelines here: https://vynetherapeutics.com/social-media-guidelines/.

Company Details

Employees
52
Founded
-
Address
520 U.s. Highway 22,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Bridgewater, NJ
Looking for a particular Vyne Therapeutics Inc. employee's phone or email?

Vyne Therapeutics Inc. Questions

News

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - Yahoo Finance

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 Yahoo Finance

VYNE Therapeutics Provides Update on VYN202 Program - GlobeNewswire

VYNE Therapeutics Provides Update on VYN202 Program GlobeNewswire

VYNE's Psoriasis Drug Shows Promise as FDA Partially Lifts Clinical Hold, Cash Position Strengthens - Stock Titan

VYNE's Psoriasis Drug Shows Promise as FDA Partially Lifts Clinical Hold, Cash Position Strengthens Stock Titan

VYNE's Vitiligo Drug Shows Mixed Results: 43% Improvement in High-Dose Group Despite Trial Miss - Stock Titan

VYNE's Vitiligo Drug Shows Mixed Results: 43% Improvement in High-Dose Group Despite Trial Miss Stock Titan

VYNE Therapeutics Completes Enrollment in Phase 2b Trial for Repibresib Gel in Nonsegmental Vitiligo - Quiver Quantitative

VYNE Therapeutics Completes Enrollment in Phase 2b Trial for Repibresib Gel in Nonsegmental Vitiligo Quiver Quantitative

VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz

VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development citybiz

VYNE's Psoriasis Drug Shows 90% Disease Reduction: FDA Allows Female Patient Trials to Resume - Stock Titan

VYNE's Psoriasis Drug Shows 90% Disease Reduction: FDA Allows Female Patient Trials to Resume Stock Titan

First Patients Dosed with VYN202 for Inflammatory Diseases - Dermatology Times

First Patients Dosed with VYN202 for Inflammatory Diseases Dermatology Times

VYNE Therapeutics Announces Reverse Stock Split - SEC.gov

VYNE Therapeutics Announces Reverse Stock Split SEC.gov

VYNE Therapeutics Provides Updates on VYN201 for Nonsegmental Vitiligo and VYN202 for Inflammatory Diseases - Dermatology Times

VYNE Therapeutics Provides Updates on VYN201 for Nonsegmental Vitiligo and VYN202 for Inflammatory Diseases Dermatology Times

VYNE Therapeutics Initiates Phase 2b Trial of BET Inhibitor VYN201 for Vitiligo - Dermatology Times

VYNE Therapeutics Initiates Phase 2b Trial of BET Inhibitor VYN201 for Vitiligo Dermatology Times

Here's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash Wisely - Yahoo Finance

Here's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash Wisely Yahoo Finance

VYNE Unblinds Early VYN202 Data After Safety Pause - Dermatology Times

VYNE Unblinds Early VYN202 Data After Safety Pause Dermatology Times

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo - Yahoo Finance

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo Yahoo Finance

Phase 2b Repibresib Study Falls Short of Key Goals - Dermatology Times

Phase 2b Repibresib Study Falls Short of Key Goals Dermatology Times

VYNE Completes Phase 2b Enrollment for Vitiligo Gel - Dermatology Times

VYNE Completes Phase 2b Enrollment for Vitiligo Gel Dermatology Times

2024 Vitiligo Breakthroughs - Dermatology Times

2024 Vitiligo Breakthroughs Dermatology Times

Journey of Vyne's topical drugs continues with $20M deal - Fierce Pharma

Journey of Vyne's topical drugs continues with $20M deal Fierce Pharma

Menlo Therapeutics Announces Results from Two Phase 3 - GlobeNewswire

Menlo Therapeutics Announces Results from Two Phase 3 GlobeNewswire

VYNE Stock Price and Chart — NASDAQ:VYNE - TradingView

VYNE Stock Price and Chart — NASDAQ:VYNE TradingView

Menlo Therapeutics and Cutia Therapeutics Enter into - GlobeNewswire

Menlo Therapeutics and Cutia Therapeutics Enter into GlobeNewswire

Foamix and Menlo Therapeutics to Merge, Creating a Combined - GlobeNewswire

Foamix and Menlo Therapeutics to Merge, Creating a Combined GlobeNewswire

Top Vyne Therapeutics Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant